Loading
Life sciences · Journal article
Frontiers in Oncology · October 28, 2026
No summary has been generated for this record yet. What follows is drawn from its source metadata only.
Journal article.
No findings were extractable from the material analysed.
Safety was not reported in the material analysed. Check the source before drawing any conclusion about harm.
The source did not state who this applies to in practice.
Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.
This record has not been graded across any dimension yet. Treat the label above as provisional and read the source.
What is missing. This record has no bottom line, key findings, reported figures, evidence dimensions. That is a gap in the analysis, not a judgement about the study.
Multiple myeloma (MM) is an incurable hematological cancer of monoclonal plasma cells, where patients commonly develop osteolytic bone disease. The pathogenesis of myeloma is known to be strongly dependent on the bone marrow (BM) microenvironment, but despite this, successful therapies targeting the niche constituents are lacking. Increased body weight and obesity are associated with poor prognosis and disease outcome, making adipose tissue an important regulatory factor in myeloma. Bone marrow adipose tissue (BMAT) has been recognized as a unique adipose depot, with strong implications in MM bone disease. In this review, we discuss the development of advanced adipose tissue models, including BMAT, and their utility for the design of precise and potentially personalized myeloma therapies. Compared to other adipose models, BMAT models require a complex composition to mimic the BM niche, including BM adipocytes, extracellular matrix, immune cells, bone cells, distinct stem/progenitor cell populations plus myeloma cells. In this sense, BMAT-permissive multicellular 3D models, such as bone and BM organoids, could have significant potential to recapitulate the MM niche. Although advanced 3D models based on induced pluripotent stem cells recreate the mesenchymal–vascular–hematopoietic tissues and BM microenvironment, adult BM recapitulation is still challenging. Incorporating patient-derived cells such as myeloma cells and BM adipocytes into these models will improve the accuracy of determining drug responses, disease progression, and patient-specific therapies, particularly in relapsed and/or refractory MM. Altogether, advanced patient-derived 3D model systems provide a more reliable experimental platform for mechanistic and translational studies across the whole BM and bone ecosystem.